Connect with us

Cannabis News

Yield Growth To License 6 CBD Product Formulas To Melorganics For Europe Market

Published

on

Yield-Growth-to-License-6-CBD-Product-Formulas-to-Melorganics-for-Europe-Market

YIELD GROWTH Licenses For 6 CBD Formulas To Melorgnics For $900,000

In August 25, 2019, Yield Growth Corporation entered into an agreement with Melorganics Hellas. The licensing and distribution agreement covers the rights to 6 CBD infusion formulas for the European market. Yield Growth will pay Melorganics $900,000 in the form of Melorganics Units, for the said rights.

The agreement acknowledges Melorganics’ ability to formulate and manufacture high-quality CBD products. In addition to the formulation of CBD- and cannabinoid-infused products, Yield also expects Melorganics to make these products available in the European Union. Melorganics will develop the brand for the market.

Yield Growth will provide the final approval of the brand name of the CBD products, including their packaging. Yield will buy $900,000 worth of Melorganics Units, giving the company 18 percent ownership of Melorganics. The agreement gives Yield the right to name the individual to head Melorganics’ Board of Directors.

Yield Growth CEO, Penny Green, said,

“We are excited to expand our relationship with Melorganics to bring our CBD products into Europe both as a new brand to be developed and also through the Wright & Well brand. The quality of our products and the strength of our brands allow us to continue to generate revenue and build our assets to bring value to our shareholders.”

Melorganics is also Yield’s exclusive distributor for the company’s Urban Juve brands in Cyprus and Greece. Melorganics need to purchase at least $300,000 worth of Urban Juves in the first year. In the succeeding years, Melorganics has to purchase at least $500,000 of Yield’s products to maintain exclusivity in Cyprus and Greece.

Melorganics Hellas President, Tom Vachliotis, said,

“We are delighted to partner with Yield Growth and now also have access to the Wright & Well Brand. Multiple SKUs is the best way to enter any market. Now when the product lines are also outstanding in quality, you really can't go wrong.”

Yield Growth is processing the registration of the different products under its Urban Juve brand throughout the European Union. The move is to allow these products to be sold in the EU market. To date, there are 2 Urban Juve products approved for sale. There are 9 more that the company expects to complete their registration by fall.

Yield is issuing $0.30-worth special warrants to help finance $500,000. The special warrants can be converted into units at a share to warrant ratio of 1:1. Entities can also buy additional shares at a share price of $0.35 for 2 years.

Phelistus Komu is esteemed contributor and expert writer with over a decade of experience in writing about health and legal topics. She received her Bachelor of Laws from Makerere University in 2007 from Rwanda.  While her main focuses are health, family and legal matters, she believes everything is possible with a willing and believing heart.  

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.